

hindered and the interaction between AVC and the second inhibitor added is no longer merely competitive. Although the data of displacement experiments using two CCR5 inhibitors discussed above may not offer a clear mechanistic explanation at present due to the limitation of the currently available methodologies, the data may have a clinical relevance in the future because more than one CCR5 inhibitor may be simultaneously administered when multiple CCR5 inhibitors are introduced in the therapy of AIDS. It is also noteworthy that the tight CCR5 binding profile of AVC is presumably related to the extensive and prolonged CCR5 occupancy observed in phytohemagglutinin-activated peripheral blood mononuclear cells ($t_{1/2} \sim 9$ h) (12) and in circulating lymphocytes in HIV-1-negative and HIV-1-positive individuals ($t_{1/2}$ of 69–152 h depending on different AVC doses), a potentially favorable feature that could enable once daily (QD) or twice daily (BID) administration of AVC.

In the present study, we observed that amino acid mutations within the transmembrane domains such as Y108A, G163R, and I198A exerted only minimal or moderate effects on the binding of CC-chemokines to CCR5 (Fig. 8B), whereas they caused a substantial reduction in HIV-1-gp120/CD4 complex binding to CCR5 (Fig. 8A) and a more drastic reduction in the susceptibility to HIV-1 infection (Fig. 8C). It is possible that the molecular size of the gp120/CD4 complex is far greater and its interactions with CCR5 are more extensive compared with the case of CC-chemokines, and therefore, the process for establishing HIV-1 infection is more extensively affected by such amino acid substitutions in comparison to CCR5 binding of CC-chemokines and the ensuing signal transduction. In this regard, a large body of literature has shown that CCR5 regions to which the envelope glycoproteins of HIV-1 bind are functionally and structurally quite different from those to which CC-chemokines bind (19–21, 32, 33). Wu *et al.* (20) and Lee *et al.* (21) demonstrated that a group of NH₂ terminus-specific CCR5 monoclonal antibodies did not block the binding of or Ca²⁺ flux induction by CC-chemokines, although ECL2-specific monoclonal antibodies effectively block the binding of CC-chemokines and their Ca²⁺ flux induction. Navenot *et al.* (33) subsequently confirmed these notions and further demonstrated that a CCR5 chimera with the NH₂ terminus of CXCR2 bound MIP-1 α with an affinity similar to that of CCR5_{WT}. In contrast, both NH₂ terminus- and ECL2-specific mAbs reportedly blocked efficiently the binding of gp120 to CCR5 although the latter mAbs caused superior inhibition (20, 21). These previously published data strongly suggest that the interactions of CCR5 with HIV-1-glycoproteins involve multiple CCR5 domains and consist of more complex processes, whereas those with CC-chemokines involve fewer CCR5 domains and potentially fewer processes. Thus, this implies that the intervention of HIV-1 infection without interrupting physiological CC-chemokine/CCR5 interactions should be feasible. Indeed, AVC does not potentially block the physiologic CC-chemokine/CCR5 interactions, although it highly efficiently suppresses the infection of HIV-1 with IC₅₀ values of subnanomolar concentrations (11).

Taken together, mutations associated with AVC binding to CCR5 decreased gp120 binding to CCR5 and the susceptibility to HIV-1 infection, whereas mutations in TM4 and TM5 that also decreased gp120 binding and HIV-1 infectivity had less effects on the binding of CC-chemokines, suggesting that CCR5 inhibition targeting appropriate regions might render the inhibition highly HIV-1-specific, preserving the CC chemokine-CCR5 interactions. The present data should not only help design more potent and HIV-1-specific CCR5 inhibitors, but also should give new insights into the dynamics of CC-chemokine-CCR5 interactions and the mechanisms of CCR5 involvement in the process of cellular entry of HIV-1.

Interactions of CCR5 Inhibitors with CCR5

Acknowledgments—We thank Steve LaFon, James Demarest, Alphonso Nillas, Larry Boone, Yashuhiro Koh, Yosuke Maeda, and Philip Yin for helpful discussion and/or critical reading of the manuscript. We also thank the Center for Information Technology, National Institutes of Health, for providing computational resources.

REFERENCES

- Fauci, A. S. (2003) *Nat. Med.* **9**, 839–843
- Mitsuya, H., and Erickson, J. (1999) in *Textbook of AIDS Medicine* (Merigan, T. C., Bartlett, J. G., and Bolognesi, D., eds) pp. 751–780, Williams and Wilkins, Baltimore
- Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., and Siliciano, R. F. (2003) *Nat. Med.* **9**, 727–728
- Richman, D. D. (2001) *Nature* **410**, 995–1001
- Department of Health and Human Services (DHHS) (2005) *Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents*
- Raport, C. J., Gosling, J., Schweickart, V. L., Gray, P. W., and Charo, I. F. (1996) *J. Biol. Chem.* **271**, 17161–17166
- Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., and Berger, E. A. (1996) *Science* **272**, 1955–1958
- Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhardt, M., Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996) *Nature* **381**, 661–666
- Trkola, A., Dragic, T., Arthos, J., Binley, J. M., Olson, W. C., Allaway, G. P., Cheng-Mayer, C., Robinson, J., Maddon, P. J., and Moore, J. P. (1996) *Nature* **384**, 184–187
- Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A. A., Desjardins, E., Newman, W., Gerard, C., and Sodroski, J. (1996) *Nature* **384**, 179–183
- Maeda, K., Nakata, H., Koh, Y., Miyakawa, T., Ogata, H., Takaoka, Y., Shibayama, S., Sagawa, K., Fukushima, D., Moravsek, J., Koyanagi, Y., and Mitsuya, H. (2004) *J. Virol.* **78**, 8654–8662
- Nakata, H., Maeda, K., Miyakawa, T., Shibayama, S., Matsuo, M., Takaoka, Y., Ito, M., Koyanagi, Y., and Mitsuya, H. (2005) *J. Virol.* **79**, 2087–2096
- Baba, M., Nishimura, O., Kanazaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K., and Fujino, M. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 5698–5703
- Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., Greenlee, W. J., Tagat, J. R., McCombie, S., Cox, K., Fawzi, A. B., Chou, C. C., Pugliese-Sivo, C., Davies, L., Moreno, M. E., Ho, D. D., Trkola, A., Stoddart, C. A., Moore, J. P., Reyes, G. R., and Baroudy, B. M. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98**, 12718–12723
- Gribble, G. W. (1975) *J. Chem. Soc. Chem. Commun.* 535–541
- Evans, E. A. (1974) in *Tritium and Its Compounds* (Evans, E. A., ed) pp. 271–317, J. Wiley and Sons, New York
- Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D., and Mitsuya, H. (2001) *J. Biol. Chem.* **276**, 35194–35200
- Maeda, Y., Foda, M., Matsushita, S., and Harada, S. (2000) *J. Virol.* **74**, 1787–1793
- Siliciano, J. D., Kuhmann, S. E., Weng, Y., Madani, N., Springer, M. S., Lineberger, J. E., Danzeisen, R., Miller, M. D., Kavanaugh, M. P., DeMartino, J. A., and Kabat, D. (1999) *J. Biol. Chem.* **274**, 1905–1913
- Wu, L., LaRosa, G., Kassam, N., Gordon, C. J., Heath, H., Ruffing, N., Chen, H., Humblias, J., Samson, M., Parmentier, M., Moore, J. P., and Mackay, C. R. (1997) *J. Exp. Med.* **186**, 1373–1381
- Lee, B., Sharron, M., Blanpain, C., Doranz, B. J., Vakili, J., Setoh, P., Berg, E., Liu, G., Guy, H. R., Durell, S. R., Parmentier, M., Chang, C. N., Price, K., Tsang, M., and Doms, R. W. (1999) *J. Biol. Chem.* **274**, 9617–9626
- Maeda, Y., Venzon, D. J., and Mitsuya, H. (1998) *J. Infect. Dis.* **177**, 1207–1213
- Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) *Science* **289**, 739–745
- Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., and Banks, J. L. (2004) *J. Med. Chem.* **47**, 1750–1759
- Xiang, Z., and Honig, B. (2001) *J. Mol. Biol.* **311**, 421–430
- Kaminski, G. A., Friesner, R. A., Tirado-Rives, J., and Jorgensen, W. J. (2001) *J. Phys. Chem. B* **105**, 6474–6487
- Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) *J. Med. Chem.* **47**, 1739–1749
- Exner, T. E., Keil, M., Moeckel, G., and Brickmann, J. (1998) *J. Mol. Model.* **4**, 340–343
- Viswanadhan, V. N., Ghose, A. K., Revankar, G. R., and Robins, R. K. (1989) *J. Chem. Inf. Comput. Sci.* **29**, 163–172

Interactions of CCR5 Inhibitors with CCR5

30. Dragic, T., Trkola, A., Thompson, D. A., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O., Sakmar, T. P., and Moore, J. P. (2000) *Proc. Natl. Acad. Sci. U. S. A.* 97, 5639–5644
31. Tsamis, F., Gavrilov, S., Kajumo, F., Seibert, C., Kuhmann, S., Ketas, T., Trkola, A., Palani, A., Clader, J. W., Tagat, J. R., McCombie, S., Baroudy, B., Moore, J. P., Sakmar, T. P., and Dragic, T. (2003) *J. Virol.* 77, 5201–5208
32. Dragic, T., Trkola, A., Lin, S. W., Nagashima, K. A., Kajumo, F., Zhao, L., Olson, W. C., Wu, L., Mackay, C. R., Allaway, G. P., Sakmar, T. P., Moore, J. P., and Maddon, P. J. (1998) *J. Virol.* 72, 279–285
33. Navenot, J. M., Wang, Z. X., Trent, J. O., Murray, J. L., Hu, Q. X., DeLeeuw, L., Moore, P. S., Chang, Y., and Peiper, S. C. (2001) *J. Mol. Biol.* 313, 1181–1193
34. Blanpain, C., Lee, B., Vakili, J., Doranz, B. J., Govaerts, C., Migeotte, I., Sharron, M., Dupriez, V., Vassart, G., Doms, R. W., and Parmentier, M. (1999) *J. Biol. Chem.* 274, 18902–18908
35. Govaerts, C., Bondue, A., Springael, J. Y., Olivella, M., Deupi, X., Le Poul, E., Wodak, S. J., Parmentier, M., Pardo, L., and Blanpain, C. (2003) *J. Biol. Chem.* 278, 1892–1903
36. Sarafianos, S. G., Das, K., Hughes, S. H., and Arnold, E. (2004) *Curr. Opin. Struct. Biol.* 14, 716–730
37. Sparks, S., Adkison, K., Shachoy-Clark, A., Piscitelli, S., and Demarest, J. (2005) *12th Conference on Retroviruses and Opportunistic Infections, Boston, February 22–25, 2005*, Abstr. 77, Foundation for Retrovirology and Human Health, Alexandria, VA
38. Lalezari, J., Thompson, M., Kumar, P., Piliero, P., Davey, R., Murtaugh, T., Patterson, K., Shachoy-Clark, A., Adkinson, A., Demarest, J., Sparks, S., Fang, L., Lou, Y., Berrey, M., and Piscitelli, S. (2004) *44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, February 22–25, 2005*, Abstr. H-1137b, Foundation for Retrovirology and Human Health, Alexandria, VA



2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: A nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma

Hiroshi Ohru¹, Satoru Kohgo², Hiroyuki Hayakawa², Eiichi Kodama³, Masao Matsuoka³, Tomohiro Nakata⁴ and Hiroyuki Mitsuya^{4,5}

¹Yokohama College of Pharmacy, Yokohama, Japan, ²Yamasa Corporation, Chiba, Japan, ³Institute for Virus Research, Kyoto, Japan, ⁴Kumamoto University, School of Medicine, Kumamoto, Japan and ⁵National Cancer Institute/National Institute of Health, Bethesda, Maryland, USA

ABSTRACT

A working hypothesis to solve the critical problems of existing HAART was proposed. The study based on the hypothesis proved the validity of the hypothesis and resulted in the development of 2'-deoxy-4'-C-ethynyl-2-fluoro-adenosine (4'Ed2FA), a nucleoside reverse transcriptase inhibitor (NRTI) with highly potent activity against all HIV-1 strains, very favourable toxic profiles, and stability in plasma.

INTRODUCTION

HAART has dramatically improved the q. o. l. and prognosis of patients infected with HIV-1. However, the existing HAART has critical problems. They are

- 1) emergence of drug-resistant HIV variants,
- 2) requirement of frequent and large doses of drugs,
- 3) side effects of drugs.

A working hypothesis to solve the problems was proposed based on the fundamentals of both organic chemistry and biochemistry, and past findings of relationship between biological activity and structure of nucleoside derivatives.

The hypothesis is comprised of the following three ways.

1) **The way to prevent emergence of drug-resistant HIV**
All clinical NRTIs belong to the family of 2',3'-dideoxynucleoside (ddN). The ddN structure has been assumed essential for nucleoside derivative to be anti-HIV active, i.e. to be the chain terminator of proviral DNA biosynthesis. However, HIV variants resistant to all these clinical NRTIs emerged. Resistance to these ddNs means that HIV can acquire the ability to discriminate between ddN and physiologic 2'-deoxynucleoside (dN) and does not accept ddN into the active center of its reverse transcriptase (RT) and/or selectively cut off the incorporated ddN from its proviral DNA terminus. Thus, resistance is the discrimination by HIV. Therefore, the nucleoside (N) that could prevent the emergence of drug-resistant HIV variants must satisfy the following conditions.

(1) To prevent discrimination by HIV, N must have the structure very much like dN. Therefore, N must have 3'-OH.

(2) In spite of having 3'-OH, N must be the chain terminator of proviral DNA biosynthesis. 2'-deoxy-4'-C-substituted nucleoside (4'SdN) was designed as the nucleoside that can satisfy these conditions on the basis of the following hypothesis.

- (a) It will be difficult for HIV to discriminate between 4'SdN and dN because 4'SdN has all the functional groups of dN.
- (b) The neopentyl-type secondary 3'-OH of 4'SdN would be too unreactive to be used for elongation of proviral DNA biosynthesis. Thus, 4'SdN could be the chain-terminator of proviral DNA biosynthesis.

2) The way to decrease the toxicity of nucleosides


In 1960s and 1970s, organic chemists synthesized nucleoside derivatives modified at two or more than two positions of physiologic nucleosides expecting to get nucleoside derivatives with excellent biological activity. However, none of them showed remarkable biological activity. These results suggested that the intracellular important enzymes do not recognize these modified nucleosides as their substrates. Therefore, the toxicity of 4'SdN could be decreased by additional modification.

3) The way to provide nucleosides with stability to both enzymatic and acidic glycolysis

The lone pair of the ring oxygen plays an important role in both enzymatic and acidic glycolysis of nucleosides by participating to form an oxocarbenium ion. The steric hindrance between the 4'-substituent and 3'-OH of 4'SdN changes the ring conformation into 3'-endo (N-type). It will be difficult for the lone pair of the ring oxygen of 4'SdN with 3'-endo conformation to form oxocarbenium ion because the three bonds, C4-O-C1-C2, can not be co-planar easily. Thus, the introduction of a substituent at the 4'-position of nucleosides provide them with stability to both enzymatic and acidic glycolysis.

RESULTS AND DISCUSSION

Studies based on the hypothesis have proved the validity of the hypothesis. Optimization of the 4'-substituents, bases, and their combinations has resulted in the development of 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine (**4'Ed2FA**, a nucleoside modified at two positions (4' and 2) of physiologic deoxyadenosine, which is highly active against all existing HIV strains has low toxicity, and is stable to both enzymatic and acidic glycolysis.

The results of the biological evaluation of **4'Ed2FA**

1) Anti-HIV activity:

EC₅₀ (wild type)=0.2 nM; AZT=22 nM, (MDR)=0.14 nM; AZT=15,300 nM, (M184V)=3.1 nM; AZT=10 nM.

2) Toxicity:

DNA polymerase α : IC₅₀>200 μ M,

DNA polymerase β : IC₅₀>200 μ M,

Human mitochondrial DNA polymerase γ : IC₅₀=10 μ M.

ddA: IC₅₀=0.2 μ M

Mouse Toxicity: No acute toxicity up to 100 mg/kg by both oral and intravenous administration.

3) Stability to enzymatic and acidic glycolysis

Half life time of triphosphate of **4'Ed2FA**: T_{1/2}: ~18hr,

triphosphate of AZT: T_{1/2}= 3hr

About 50% of the cells were protected against the infection of HIV-1 for 24 hr after removal of extracellular **4'Ed2FA** in both MT4 cells and MAGI cells cultured in the presence of 0.1 μ M of **4'Ed2FA**.

Completely stable to adenosine deaminase under the conditions where **4'EdA** was completely deaminated within 60 min.

Only a small part (3 %) was hydrolyzed under the acidic conditions of gastric juice (pH 1.06) at 24 °C, while **ddA** was completely decomposed in 5 min.

SUMMARY

A study on the synthesis and biological evaluation of **4'SdNs** was conducted according to a proposed hypothesis based on the fundamentals of both organic chemistry and biochemistry. Old findings proved the validity of the hypothesis and resulted in the development of **4'Ed2FA**, which is highly potent against all HIV-1s, is stable to intracellular catabolism and acidic degradation, has a very

long intracellular T_{1/2}, does not greatly inhibit DNA polymerase γ and does not have acute mouse toxicity. These results strongly suggest that **4'Ed2FA** deserves further study for the development of a highly potent therapeutic agent for HIV infection (AIDS), which may solve the problems of the existing HAART.

In addition, it should be noted that **4'Ed2FA** could be the ideal drug for both HIV and HBV infections. Hepatitis B virus (HBV) is a DNA virus, however, it also belongs to the family of retrovirus because it uses reverse transcriptase (RT) when it replicates. It was found that the NRTIs of HIV are also active against HBV, and 3TC has been used for HBV infection.^{9,10} However, HBV resistant to 3TC has emerged. Since **4'Ed2FA** is highly active against 3TC-resistant HIV and will prevent the emergence of drug-resistant HIV, it is also expected to be active against drug-resistant HBV. Thus, **4'Ed2FA** could be the ideal drug for use against both HIV and HBV.

REFERENCES

1. Waga, T., Ohru, H., Meguro, H. (1996) *Nucleosides Nucleotides*, **57**, 287.
2. Yamaguchi, T., Tomikawa, A., Hirai, T., Kawaguchi, T., Ohru, H., Saneyoshi, M. (1997) *Nucleosides Nucleotides*, **16**, 1347.
3. Ohru, H., Kohgo, S., Kitano, K., Sakata, S., Kodama, E., Yoshimura, K., Matsuoka, M., Shigeta, S., Mitsuya, H. (2001) *J. Med. Chem.*, **65**, 1879.
4. Kodama, E., Kohgo, S., Kitano, K., Machida, H., Gatanaga, H., Shigeta, S., Matsuoka, M., Ohru, H., Mitsuya, H. (2001) *Antimicrobial Agents & Chemotherapy*, **45**, 1539.
5. Ohru, H., Mitsuya, H. (2001) *Current Drug Targets-Infectious Disorder*, **1**, 1.
6. Kohgo, S., Yamada, K., Kitano, K., Iwai, Y., Sakata, N., Hayakawa, H., Nameki, D., Kodama, E., Matsuoka, M., Ohru, H., Mitsuya, H. (2004) *Nucleosides Nucleotides*, **23**, 671.
7. Patent: International Publication Number, WO2005/090349, PCT/JP2005/005374
8. Nakata, H., Amano, M., Koh, Y., Kodama, E., Yang, G., Kohgo, S., Hayakawa, H., Ohru, H., Matsuoka, M., Mitsuya, H. (2006) Abstract of 13th Conference on Retroviruses and Opportunistic Infections (CRO), F (antiviral therapy-preclinical), p219 (poster).
9. Lai, C. L., Dienstag, J., Schiff, E., Leung, N. W. Y., Akins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., Condreay, L. (2003) *Clin. Infect. Dis.*, **36**, 687.
10. Villeneuve, J. P., Durantel, D., Durantel, S., Westland, C., Xiong, S., Brosgart, C. L., Bibbs, C. S., Parvas, P., Nerle, B., Trepo, C., Zoulim, F. J. (2003) *Heptol.*, **39**, 1085.

Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite

Rena Nishizawa,^{a,*} Toshihiko Nishiyama,^a Katsuya Hisaichi,^a Naoki Matsunaga,^a Chiaki Minamoto,^a Hiromu Habashita,^a Yoshikazu Takaoka,^a Masaaki Toda,^a Shiro Shibayama,^b Hideaki Tada,^b Kenji Sagawa,^b Daikichi Fukushima,^b Kenji Maeda^c and Hiroaki Mitsuya^{c,d}

^aMedicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, Osaka 618-8585, Japan

^bExploratory Research Laboratories, Ono Pharmaceutical Co., Ltd, Ibaraki 300-424, Japan

^cDepartment of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan

^dExperimental Retrovirology Section, HIV & AIDS Malignancy Branch, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA

Received 17 August 2006; revised 23 October 2006; accepted 26 October 2006

Available online 1 November 2006

Abstract—Hydroxylated derivatives were designed and synthesized based on the information of oxidative metabolites. Compounds derived from β -substituted (2*R*,3*R*)-2-amino-3-hydroxypropionic acid showed improved inhibitory activities against the binding of MIP-1 α to human CCR5, compared with the non-hydroxylated derivatives and the other isomers.
© 2006 Elsevier Ltd. All rights reserved.

Millions of people in the world are still suffering from acquired immune deficiency syndrome (AIDS).¹ Although the highly active antiretroviral therapy (HAART), a cocktail of protease and reverse transcriptase inhibitors, has been useful for many patients, several issues still remain for anti-HIV therapy: a gradual spread of drug-resistant strains, severe adverse effects, expensive therapeutic cost, etc.² These issues require new anti-HIV drugs to have a different mode of action from conventional drugs.

Agents inhibiting HIV entry into target cells are one of the most promising approaches to treat AIDS.³ A number of potential sites for therapeutic intervention become accessible during the narrow window between virus attachment and the subsequent fusion of viral envelope with the cell membrane. In 1996, it was revealed that one of the C–C chemokine receptor 5 (CCR5) is utilized by HIV-1 as an essential co-receptor and that the endogenous ligand showed anti-HIV-1 activity in vitro.⁴ CCR5 belongs to the superfamily of

G protein-coupled receptors (GPCRs), which greater than 30% of all known marketed medicines modulate the function of.⁵ After these reports, many pharmaceutical companies and academic institutions have been enthusiastically investigating novel antagonists against CCR5 with suitable pharmaceutical properties.⁶

We previously reported the identification of several spirodiketopiperazine derivatives, for example, **1** (Fig. 1), from a combinatorial library targeting chemokine receptors.⁷ Compound **1** not only selectively inhibited the binding of macrophage inflammatory protein (MIP)-1 α to human CCR5 receptor, but also potently blocked the infectivity and replication of laboratory and clinical strains of HIV as well as those of highly drug-resistant HIV variants with minimal cytotoxicity.⁸ Although




Figure 1. The structure of lead compound **1**.

Keywords: CCR5; HIV-1; Active metabolite.

* Corresponding author. Tel.: +81 75 961 1151; fax: +81 75 962 9314; e-mail: r.nishizawa@ono.co.jp




Figure 2. Metabolites of the compound 1. Three main metabolites were identified on LC-MS after incubation with human liver microsome (5.0 mg protein/ml) for 1.5 h.


compound 1 showed potent activity *in vitro*, oxidative metabolism in liver microsomes resulted in low bioavailability in rodents.

After the incubation with human liver microsomes, metabolites of 1 were purified by HPLC. The three major isolated metabolites (a, b, c in Fig. 2) were analyzed by LC-MS and ^1H NMR, and found to be compounds hydroxylated on the *n*-butyl and/or the *i*-butyl group.⁹ Additionally, we evaluated the *in vitro* antagonistic activity of each isolated metabolite. Fortunately, the samples of the peaks (b) and (c) showed significant antagonistic activities (data not shown). This information prompted us to try the introduction of hydroxyl group on side chains to improve the *in vitro* activity as well as pharmaceutical properties. Herein, we describe the preliminary structure–activity relationship (SAR) of the hydroxylated-spirodiketopiperazines and the unexpected improvement on the activities, especially *in vitro* anti-HIV activities.

The compounds 1, 5, 7, 8, and 12 were synthesized from the *N*-alloc-4-piperidone, the corresponding amine, the corresponding *N*-Boc-amino acid, and 4-phenoxybenz-

aldehyde by the reported solid-phase synthesis.⁷ The compounds 9–11 and 13 were synthesized from the corresponding amino acid derivatives by the identical procedure to the synthesis of compound 4 shown in Scheme 1. The mixture of 1-benzylpiperidone, butylamine, *N*-Boc- β -hydroxy-D-leucine, and 2-(4-morpholinyl)ethylisocyanide¹⁰ in methanol was stirred at 55 °C.¹¹ The enantiomerically pure β -hydroxy- α -amino acids were prepared according to the reported method through Sharpless asymmetric epoxidation from the corresponding allyl alcohol.¹² The Boc protecting group of amino acid was removed by the treatment of concentrated HCl without isolation of the Ugi product. Cyclization of the obtained crude product by heating in toluene in the presence of acetic acid at 80 °C followed by the removal of the benzyl group by catalytic hydrogenation afforded the cyclized spirodiketopiperazine, and compound 3 was isolated as a HCl salt in acceptable yield. Reductive alkylation of compound 3 resulted in desired product 4 in high yields.

The compounds listed in Tables 1–3 were evaluated for their inhibitory activities against calcium mobilization of human CCR5 overexpressed CHO cell (hCCR5/



Scheme 1. Typical synthetic route for spirodiketopiperazines. Reagents and condition: (a) MeOH, 55 °C; (b) coned HCl, 55 °C; (c) AcOH/toluene, 80 °C; (d) H_2 , Pd(OH)₂/C, EtOH, 55 °C then 4 N HCl/AcOEt (60–70% in four steps); (e) 4-phenoxybenzaldehyde, NaBH(OAc)₃, AcOH, DMF then 4 N HCl/AcOEt (80%).

Table 1. Activity of the compounds 5 and 6










| Compound | Structure | IC ₅₀ | |
|----------|---|--------------------|---------------|
| | | Binding assay (nM) | Ca assay (nM) |
| 1 |  | 8.3 | 94 |
| 5 |  | Not tested | Ca. 10,000 |
| 6 |  | 28 | 79 |



Table 2. Activity of the stereoisomers 4 and 7–11

| Compound | Structure | IC ₅₀ | |
|---------------------------|---|--------------------|---------------|
| | | Binding assay (nM) | Ca assay (nM) |
| 7 <i>R</i> form |  | 29 | 130 |
| 8 <i>S</i> form |  | 11 | 84 |
| 4 (<i>3R,1'R</i>) form |  | 3.5 | 33 |
| 9 (<i>3R,1'S</i>) form |  | 24 | 210 |
| 10 (<i>3S,1'R</i>) form |  | 68 | 400 |
| 11 (<i>3S,1'S</i>) form |  | 53 | 150 |

CHO) stimulated by MIP-1 α (Ca assay) and for their CCR5 binding affinity by the inhibition of ¹²⁵I-MIP-1 α binding to hCCR5/CHO (binding assay).^{8,13}

The compound 5, the proposed structure of metabolite (a), was synthesized from the 3-hydroxy-1-butylamine and *N*-Boc-leucine as a mixture containing the same

Table 3. Antagonistic activity and anti-HIV activity in compounds 12 and 13

| Compound | Structure | Binding assay IC ₅₀ (nM) | Ca assay IC ₅₀ (nM) | Anti-HIV IC ₅₀ (nM) | MAGI assay IC ₅₀ (nM) |
|----------|---|-------------------------------------|--------------------------------|--------------------------------|----------------------------------|
| 12 |  | 6.1 | 28 | 31 | 337 |
| 13 |  | 1.1 | 53 | 0.6 | 6.0 |

quantity of all possible four isomers. The compound 6, the proposed structure of metabolite (b), was prepared from the *N*-Boc-aspartic acid derivative in racemic form.¹⁴ Compounds 5 and 6 were evaluated for their activities and the results are summarized in Table 1. Whereas the compound 5 showed significant decrease of activity in calcium mobilization assay, the compound 6 showed a comparable activity to the parent compound 1.¹⁵

Since the proposed structure of metabolite (c) had two chiral centers, we synthesized all four possible enantiomers 4 and 9–11 in optically pure form from the corresponding β -hydroxylated-leucine to evaluate their biological activities (Table 2). Whereas there was no remarkable difference between the activities of the two enantiomers, 7 and 8, in lead compound 1, there was a significant difference among the hydroxylated stereoisomers (4 versus 9–11). Compound 4 having 3*R*,1'*R*-configuration exhibited approximately 10-fold more potency than the other isomers 9–11. This result indicates that introducing hydroxyl group on the side chain at the 3-position of diketopiperazine ring could lead to a significant improvement in the interaction with the receptor. Based on the observation of this unexpectedly improved antagonistic activity of compound 4, we applied this information to compound 12 which showed more potent anti-HIV activity than compound 1. It was found that the (3*R*,1'*R*)-hydroxyl compound 13 exhibited strong inhibitory activities in both binding and Ca assays. Furthermore, investigating anti-HIV activity in the next step, compound 13 showed 6 nM of IC₅₀ value in anti-HIV assay (CCR5⁺ MAGI cell anti-infectivity single cycle assay versus the BAL strain of HIV,^{8a}), which was 50-fold stronger than non-hydroxyl analogue 12.¹⁶

We also evaluated the oral bioavailability of compounds 4 and 13 in rat. Unfortunately, the bioavailability of both compounds was less than 1% (data not shown). Further assessment and optimization are required to identify promising clinical candidates with acceptable pharmaceutical profile.

In conclusion, using metabolite data of lead compound 1, we discovered the excellent enhancement on the activity in binding and anti-HIV assays by the introduction of a β -hydroxyl group. Although the role of the hydroxyl

group is still unclear, two hypotheses have been made to explain the increase in activity. One is the formation of a new hydrogen bond between the hydroxyl group and CCR5. The other is restricting the conformation of the compound to favorably orient the side chains. Further investigations are in progress.

Introduction of the hydroxyl group could not improve the bioavailability in rodent. However, the introduction of a hydrophilic moiety on the molecule showed some favorable pharmaceutical properties.¹⁷ Further optimization of these compounds to improve their oral absorption and metabolic stability which are necessary to provide CCR5 antagonists suitable for clinical use will be discussed in our future reports.

References and notes

1. *AIDS Epidemic Update 2005* reported by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO).
2. (a) Yeni, P. *J. Hepatol.* **2006**, *44*, S100; (b) Rathbun, R. C.; Lockhart, S. M.; Stephens, J. R. *Curr. Pharm. Des.* **2006**, *12*, 1045.
3. Leonard, J. T.; Roy, K. *Curr. Med. Chem.* **2006**, *13*, 911.
4. (a) Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. *Nature* **1996**, *381*, 661; (b) Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.; Huang, Y.; Nagashima, K. A.; Cayanan, C.; Maddon, P. J.; Koup, R. A.; Moore, J. P.; Paxton, W. A. *Nature* **1996**, *381*, 667; (c) Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. A. *Science* **1996**, *272*, 1955.
5. Muller, G. *Drug Discov. Today* **2003**, *8*, 681.
6. (a) Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F.; Watson, C.; Kenakin, T. *Bioorg. Med. Chem.* **2003**, *11*, 2663; (b) Maeda, K.; Nakata, H.; Ogata, H.; Koh, Y.; Miyakawa, T.; Mitsuya, H. *Curr. Opin. Pharmacol.* **2004**, *4*, 447; (c) Palani, A.; Tagat, J. R. *J. Med. Chem.* **2006**, *49*, 2851.
7. Habashita, H.; Kokubo, M.; Hamano, S.; Hamanaka, N.; Toda, M.; Shibayama, S.; Tada, H.; Sagawa, K.; Fukushima, D.; Maeda, K.; Mitsuya, H. *J. Med. Chem.* **2006**, *49*, 4140.
8. (a) Maeda, K.; Yoshimura, K.; Shibayama, S.; Habashita, H.; Tada, H.; Sagawa, K.; Miyakawa, T.; Aoki, M.; Fukushima, D.; Mitsuya, H. *J. Biol. Chem.* **2001**, *276*,

- 35194; (b) Maeda, K.; Nakata, H.; Koh, Y.; Miyakawa, T.; Ogata, H.; Takaoka, Y.; Shibayama, S.; Sagawa, K.; Fukushima, D.; Moravek, J.; Koyanagi, Y.; Mitsuya, H. *J. Virol.* **2004**, *78*, 8654.
- ¹H NMR spectra of metabolites (a) and (c) indicated to be a single compound, respectively. However, it was difficult to determine the stereochemistry at each asymmetric center. As for the metabolite (c), the ¹H NMR data were identical to those of the compounds **4** and **11**, which indicates that this metabolite has *anti*-configuration.
 - We initially used several isocyanides, for example, benzyloisocyanide, for this reaction to yield the desired product. However, most of isocyanides were difficult to be handled because of the offensive odor. It was found that a commercially available isocyanide, 2-(4-morpholinyl)ethylisocyanide, is not malodorous, and we decided to employ this reagent for the further derivatization.
 - Domling, A.; Ugi, I. *Angew. Chem. Int. Ed.* **2000**, *39*, 3168.
 - (a) Caldwell, C. G.; Bondy, S. S. *Synthesis* **1990**, 34; (b) Nagamitsu, T.; Sunazuka, T.; Tanaka, H.; Omura, S.; Sprengeler, P. A.; Smith, A. B., III *J. Am. Chem. Soc.* **1996**, *118*, 3584, Compound **13** was synthesized from the β -hydroxy-cyclohexylalanine, which was obtained from the 3-cyclohexyl-allyl alcohol by an identical procedure to that reported in Ref. 12a.
 - All IC₅₀ values represent the average of two or more determinations, and the standard deviations were no greater than 30% from the mean.
 - Compound **6** was prepared by the reaction of methylmagnesium bromide with the benzyl ester derivative, which was obtained from the *N*-alloc-piperidone, butylamine, *N*-Boc- γ -benzyl-aspartic acid, and 4-phenoxybenzaldehyde according to the solid-phase synthesis reported in Ref. 7.
 - Compounds described herein showed selective CCR5 antagonistic activities over other chemokine receptors, for example, CCR1 and CXCR4.
 - Lack of correlation between anti-chemokine activity and anti-HIV activity has been reported by other researchers. See Ref. (a) Shankaran, K.; Donnelly, K. L.; Shah, S. K.; Guthikonda, R. N.; MacCoss, M.; Mills, S. G.; Gould, S. L.; Malkowitz, L.; Siciliano, S. J.; Springer, M. S.; Carella, A.; Carver, G.; Hazuda, D.; Holmes, K.; Kessler, J.; Lineberger, J.; Miller, M. D.; Emini, E. A.; Schleif, W. A. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3419; (b) Wood, A.; Armour, D. *Prog. Med. Chem.* **2005**, *43*, 239.
 - For example, whereas compound **12** inhibited CYP 3A4 at 9.3 μ M of IC₅₀, compound **13** did not show any significant inhibition at 30 μ M. Furthermore, compound **13** showed an improved aqueous solubility (pH 6.8) compared to compound **12** (**12**, <0.2 μ g/ml; **13**, 2.7 μ g/ml).



Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease

David A. Davis^{a,*}, Cara A. Brown^a, Kathleen E. Singer^a, Victoria Wang^a, Joshua Kaufman^b, Stephen J. Stahl^b, Paul Wingfield^b, Kenji Maeda^a, Shigeyoshi Harada^a, Kazuhisa Yoshimura^a, Pope Kosalaraksa^a, Hiroaki Mitsuya^a, Robert Yarchoan^a

^a HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 10S255, NIH, Bethesda MD 20892-1868, United States

^b Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Building 6B, Room 1B130, NIH, Bethesda MD 20892, United States

Received 4 November 2005; accepted 29 March 2006

Abstract

Peptides based on the amino (N) and carboxy (C)-terminal regions of human immunodeficiency virus type-1 (HIV-1) protease and on the C-terminus of p6^{*} can inhibit HIV-1 protease activity by preventing dimerization. We developed a peptide dimerization inhibitor, P27, that included these domains and a cell permeable domain derived from HIV-1 Tat. P27 inhibited wild type (WT) and protease inhibitor (PI)-resistant HIV-1 protease (IC₅₀: 0.23–0.32 μM). Kinetic and biochemical assays confirmed that P27 inhibits protease dimerization. Fluorescein-labeled peptide accumulated in MT-2 cells and protected acutely infected MT-2 cells from HIV-1-induced cytotoxicity (IC₅₀: 5.1 μM). P27 also inhibited p24 accumulation from H9 and U937 cells chronically infected with WT or PI-resistant HIV-1. Immunoblot analysis on the supernatants and infected cells revealed a block in virus release by P27 rather than an inhibition of polyprotein processing. However, inhibition of p55 Gag processing by active-site inhibitors was enhanced when combined with P27, suggesting that P27 can affect protease function in maturing virions. Although P27 was rationally designed to block dimerization of the mature HIV-1 protease, the effects of P27 on HIV-1 replication may be related to partial inhibition of Gag-Pol processing leading to a disruption in virus release.

Published by Elsevier B.V.

Keywords: HIV-1; Protease; Dimer; Peptide; Inhibitor; Polyprotein

1. Introduction

A number of HIV-1 protease inhibitors (PIs) are in clinical use for the treatment of HIV-1 infection (Deeks and Volberding, 1997; Flexner, 1998; Misson et al., 1997). These inhibitors target the active site of the protease, bind with very high affinity and prevent the production of infectious virions by infected cells. However, viral resistance to these inhibitors develops in patients as a result of HIV-1 protease mutations both near and far from the active site (Condra et al., 1995; Flexner, 1998). Certain combi-

nations of these mutations can result in cross-resistance to more than one PI (Cabana et al., 1999; Condra et al., 1995; Deeks and Volberding, 1997; Misson et al., 1997). After long-term treatment with PIs, the protease can acquire ten or more mutations and yet still remain sufficiently active to produce infectious virus (Romano et al., 2002; Schmit et al., 1996; Shafer et al., 1998; Yoshimura et al., 1999). Furthermore, mutations in Gag that alter the natural protease cleavage sites can contribute to high-level PI resistance (Gatanaga et al., 2002). For these reasons, there is a need for new strategies to contain viral replication. One active area of research has focused on alternative mechanisms to inhibit protease activity (Oxford et al., 1989).

The HIV-1 protease is an obligate dimer and therefore one potential target for protease inhibitors is the dimer interface (Babé et al., 1992, 1995; Davis et al., 1997, 2003; Schramm et al., 1999; Shultz and Chmielewski, 1999; Weber, 1990; Zutshi and Chmielewski, 2000). The interface consists of four inter-

Abbreviations: HIV-1, human immunodeficiency virus type-1; WT, wild type; PI, protease inhibitor; CPD, cell permeable domain; CPP, cell permeable peptide; RP-HPLC, reverse phase high performance liquid chromatography; PBS, phosphate-buffered saline

* Corresponding author. Tel.: +1 301 402 3630; fax: +1 301 402 3645.

E-mail address: dadavis@helix.nih.gov (D.A. Davis).

locking anti-parallel beta strands with two strands contributed from each monomer. These beta strands include the first five N terminal amino acids and the last five C terminal amino acids of each 99 amino acid protease monomer and contribute 75% of the Gibbs free energy of dimer stabilization (Todd et al., 1998). Our group has previously shown that reversible oxidation of a sulfur-containing amino acid at the dimer interface of HIV-1 or HIV-2 protease completely inhibits protease activity by blocking dimer formation (Davis et al., 1997, 2000, 2003). This data established the sensitive nature of protease dimerization to modification of the dimer interface and its potential value as a target for protease inhibitor development. Peptides mimicking the interface strands were the first compounds postulated as potential inhibitors of dimerization (Weber, 1990). The individual N and C terminal peptides can block protease activity and it was found that linking these two regions together in a single peptide using a glycine linker was even more effective (Babé et al., 1992). Others have developed peptides with different length synthetic linkers between variations of the N and C terminal peptides or potent lipopeptide dimerization inhibitors of the protease (Dumond et al., 2003; Shultz and Chmielewski, 1999; Ulysse and Chmielewski, 1998).

New methods have recently been developed for effectively delivering peptides and proteins into cells that involve attaching polycationic peptide sequences to peptides and proteins of interest (Fawell et al., 1994; Futaki et al., 2001, 2003; Richard et al., 2003; Vives et al., 1997). These polycationic peptides have been found to readily cross cell membranes in an energy-independent fashion (Futaki et al., 2001). One type of delivery involves the use of a highly basic region of the HIV-1 Tat protein that was initially found to facilitate the entry of the HIV-1 Tat protein into cells (Vives et al., 1997). Although there is uncertainty surrounding the exact mechanism by which these carrier peptides and their cargo enter and accumulate in living cells (Lundberg et al., 2003; Richard et al., 2003), several groups have demonstrated biological activity of the cargo peptides or proteins carried into the cells. Such activity has been demonstrated for inhibitors of beta cell death (Bonny et al., 2001), human catalase (Jin et al., 2001), a PKC agonist peptide (Chen et al., 2001), superoxide dismutase (Park et al., 2002), p53 (Takenobu et al., 2002), hsp70 (Wheeler et al., 2003), and a von Hippel-Lindau suppressor peptide (Datta et al., 2001). Others have described the delivery of biologically active proteins fused to a cell permeable domain (CPD) from HIV-1 Tat into the tissues of mice following injection (Schwarze et al., 1999). In this report, we describe the development of an HIV-1 protease peptide dimerization inhibitor containing a CPD from HIV-1 Tat and its effects on HIV-1 replication in acutely and chronically infected T-cells.

2. Materials and methods

2.1. Reagents

Peptides were obtained from Sigma Genosys (The Woodlands, TX). All peptides were synthesized using standard Fmoc chemistry and all peptides contained a C terminal amide. Fluorescein-labeled peptides were labeled at the N-terminus.

Each peptide was received as a lyophilized powder (>90–95% purity) and stored frozen at -20°C as a 1–2 mM solution in sterile PBS. Wild type (WT) HIV-1 protease (sequence derived from an untreated patient infected with HIV-1) and two resistant mutants termed R1 and R1_{F95C} (R1 sequence derived from a heavily PI-treated HIV-1 infected patient) (Yoshimura et al., 1999) were prepared and refolded using the methods described previously (Davis et al., 1996) and stored at -70°C at 0.6–3.5 mg ml⁻¹. Protease concentrations were determined spectrophotometrically (ϵ_{280} 12,300 M⁻¹ cm⁻¹ for HIV-1 protease) and the proteases were >95% pure based on RP-HPLC analysis.

2.2. Fluorimetric HIV-1 protease assay and kinetics

The fluorescent HIV-1 protease substrate (RE-(EDANS)-SQNYPIVQK-(DABCYL)-R) was obtained from Molecular Probes Inc. (Eugene, OR). Substrate and buffer were pre-warmed at 37°C for at least 20 min before use. For screening and time-dependent studies, the protease (25 nM final concentration) and peptides were pre-incubated in the manufacturer's recommended assay buffer (10 μl) (100 mM Na acetate, 1 M NaCl, 1 mM EDTA, 1 mM DTT, 10% DMSO and 1 mg ml⁻¹ BSA pH 4.7) at 37°C for up to 30 min and then added to 90 μl of warmed substrate solution (final concentration 40 μM) to initiate the reaction. The total assay volume was 100 μl . Fluorescence was monitored for at least 10 min in a fluorescence microplate reader (FMAX, Molecular Devices, Sunnyvale, CA) with 355 nm excitation and 460 nm emission filters. The resulting progress curves were analyzed by non-linear regression using a first-order exponential fit to obtain initial velocities and determine IC₅₀s (BatchKi, BioKin Ltd., Pullman, WA). Kinetic analysis was performed using the Zhang and Poorman equation, which measures the dissociative inhibition of dimeric enzymes (Zhang et al., 1991). For these experiments HIV-1 protease was used at concentrations from 0.79 to 3.15 nM (active dimer) and substrate was used at a concentration of 5 μM . To initiate the reactions, the enzyme was added to buffer with or without the inhibitors, and activity was monitored for 30 min. Under the assay conditions indicated above, the substrate K_m was determined to be $21 \pm 2 \mu\text{M}$. E_0/k_{exp} as a function of k_{exp} was plotted at the different enzyme concentrations tested. Each enzyme concentration with and without inhibitor was run in triplicate and the resulting progress curves were analyzed by non-linear regression using a first-order exponential fit to obtain initial velocities from BatchKi (Pullman, WA). The concentration of active protease indicated above was determined by active site titration (Tomasselli et al., 1990) and fit to the Morrison equation using Prism (San Diego, CA) (Kuzmic et al., 1992).

2.3. Fluorescent microscopy

MT-2 cells grown in 10% fetal calf serum in RPMI were incubated for 1 h with N-terminal fluorescein labeled peptide PQITLRKKRRQRRRPPQVSFNFATLNF (F-P27A) or N-terminal fluorescein labeled cell permeable peptide RKKRRQR-RRPPQVSFNF (F-CPP) at 30 μM in media containing 10%

serum. Following incubation, the cells were washed three times with fresh media, stained with trypan blue to assess cell viability and observed under phase contrast and fluorescence modes to assess uptake of fluorescein labeled peptides.

2.4. Generation of recombinant WT and PI-resistant HIV-1 molecular clones

Determination of nucleotide sequences of HIV-1 was performed as previously described (Yoshimura et al., 1999). In brief, pre-therapy HIV-1_{A01} (WT) and post-therapy HIV-1_{A2} (PI-resistant) clinical HIV-1 strains were isolated by culture from the peripheral blood mononuclear cells (PBMC) of an HIV-1 infected patient. The HIV-1 isolates were passed once in PHA-stimulated PBMC (PHA-PBMC) obtained from an HIV-1 negative donor. High molecular weight DNA was extracted from the PHA-PBMC harboring HIV-1_{A01} or HIV-1_{A2} using Instagene Matrix (Bio-Rad, Hercules, CA). The HIV-1_{A01} WT pre-therapy protease sequence contained four polymorphic amino acid substitutions when compared to the subtype B WT sequence (I15V, E35D, N37D, and I93L) but did not contain any primary resistance PI mutations as defined by Shafer et al. (2000). The HIV-1_{A2} sequence had nine mutations as compared to the pre-therapy sequence (L10I, N37E, K45R, I54V, L63P, A71V, V82T, L90M, and C95F), including three that are described as primary resistance mutations (I54V, V82T, and L90M) and that are known to confer resistance to multiple PIs (Kuiken et al., 2004; Shafer et al., 2000). The patient from whom HIV-1_{A2} was obtained had a high viral load in spite of taking anti-HIV therapy (treatment failure) at the time that this resistant protease sequence was the predominant viral isolate and was shown to be highly resistant to a variety of potent active site HIV-1 protease inhibitors in clinical use (Yoshimura et al., 1999). The entire protease-encoding region of HIV-1_{A01} and HIV-1_{A2} was amplified with *Taq* DNA polymerase from Perkin-Elmer Life Sciences (Shelton, CT) using the following two primer pairs: the forward primer1 (Kapa1) 5'-GCA GGG CCC CTA GGA AAA AGG GCT GTT GG-3' and the reverse primer1 (PR12) 5'-CTC GTG ACA AAT TTC TAC TAA TGC-3' and the forward primer2 (Kapa3) 5'-CAG GGC CCC TAG GAA AAA GGG CTG TTG GAA ATG TGG-3', the reverse primer2 (Ksma4) 5'-GGG CCA TCC ATC CCG GGC TTT AAT TTT ACT GG-3'. The forward primer contained an *ApaI* site and the reverse primer contained an *XmaI* site. The PCR products were purified with PCR Select III column (5 Prime \ddagger 3 Prime Inc., Boulder, CO) and subjected to molecular cloning using Original TA Cloning Kit (Invitrogen, Carlsbad, CA), followed by sequence determination using an Applied Biosystems model 373 automated DNA sequencer.

For the generation of a recombinant infectious molecular clone harboring the above-described WT virus protease sequence (rHIV-1_{A01}), the PCR products obtained as above were digested with two enzymes *ApaI* and *SmaI*, and the obtained fragments were introduced into pHIV-1_{NLSma} which was designed to have a *SmaI* site by changing two nucleotides (2590 and 2593) of pHIV-1_{NL4-3}. We also generated an infectious molecular clone carrying a cysteine at position 95 plus the other substitutions described for rHIV-1_{A2} (rHIV-1_{A2F95C}) by start-

ing with HIV-1_{A2} and utilizing site directed mutagenesis with the QuickChange Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA) with forward primer (95TGC1) 5'-GAC TCA GAT TGG CTG CAC TTT AAA TTT TC-3' and a reverse primer (95TGC2) 5'-GAA AAT TTA AAG TGC AGC CAA TCT GAG TC-3'. The PCR products were introduced into pHIV-1_{NLSma}, eventually generating rHIV-1_{A2F95C}. An HIV-1 isolate containing these protease resistance mutations was shown previously to be highly resistant to the protease inhibitors ritonavir, saquinavir, amprenavir, and indinavir (Yoshimura et al., 1999). Determination of the nucleotide sequences of newly generated plasmids confirmed that each clone had the desired mutations but no unintended mutations. Each recombinant plasmid was transfected into COS-7 cells with LipofectAmin (Life Technologies, Gaithersburg, MD) and infectious virions rHIV-1_{A01} and rHIV-1_{A2F95C} were harvested 48 h after transfection and stored at -80 °C until use.

2.5. Virus replication and cell viability assays

For studies on the effect of these peptides on acute infection, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed to determine the ability of compounds to protect MT-2 cells from the cytopathic effect of HIV-1_{LAI}. MT-2 cells (4×10^3 cells in 200 μ l complete medium per well) grown in RPMI-based culture medium with 10% fetal calf serum (HyClone, Logan, UT) with 50 U ml⁻¹ penicillin and 50 mg ml⁻¹ streptomycin were incubated with 100 CCID₅₀ of HIV-1_{LAI} for 2 h and then added to 96-well plates containing the test compounds giving final concentrations from 0 to 50 μ M. Lopinavir, a potent active-site inhibitor, was used as a positive control. Seven days later, 100 μ l of medium was removed and MTT solution (10 μ l, 7.5 mg ml⁻¹) was added to each well. The plates were incubated at 37 °C for 2 h and then each well treated with 100 μ l of acidified isopropyl alcohol containing 4% (v/v) TritonX-100 to dissolve the formazan crystals. The absorbance at 570 nm was then determined in a microplate reader (Spectra-max). Each assay was performed in duplicate. In this assay, the cytopathic effect of HIV-1 requires several rounds of infection and therefore is susceptible to inhibitors that act on the late stages of viral replication. The concentration of peptide required to inhibit HIV-1 induced cytotoxicity by 50% was calculated from the plot of peptide concentration versus the percent viable cells compared to the untreated HIV-1 infected control. The concentration of peptide that induced 50% cytotoxicity in uninfected cells was calculated from the plot of peptide concentration versus the percent viable cells in uninfected cells treated only with PBS.

Chronically infected cell lines were prepared by infecting H9 cells with wild type (WT, rHIV-1_{A01}) or PI-resistant virus (rHIV-1_{A2F95C}). One million cells were infected with 100 ng p24 in 1 ml of media and incubated at 37 °C for 2 h and then additional media added (15 ml) and cells maintained and passed every 5 days. The infected cells were maintained for several passages before use in inhibitor assays. Cells were grown in RPMI 1640 media (Life Technologies) containing 10% fetal calf serum (HyClone Laboratories, Logan, UT), 4 mM L-glutamine,

50 U ml⁻¹ penicillin, and 50 µg ml⁻¹ streptomycin (Life Technologies). Chronically infected U937 cells were prepared in the same way by infection with WT, rHIV-1_{A01}. H9 cells or U937 cells chronically infected with HIV-1 were washed two times with media and then plated at 250,000 cells ml⁻¹ (1 ml well⁻¹) and incubated for 2 h prior to treatment. The peptides dissolved in sterile PBS were added to wells (2.5–20 µM) and each treatment was done in triplicate. Controls were treated with an equal volume of sterile PBS. In some experiments, peptides were used in combination with active-site inhibitors to determine the effect on polyprotein processing. Three days after treatment, the supernatants were sampled for HIV-1 p24 antigen in the media using the Retrotek p24 ELISA from ZeptoMetrix Corporation that picks up the mature form of the p24 viral antigen (Buffalo, NY). The effect of the peptides on cell viability was assessed using the CellTiter-Glo™ Luminescent Cell Viability Assay that determines the level of cellular ATP (Promega, Madison, WI). Luminescence was read on the Victor2 luminometer from Perkin-Elmer (Boston, MA).

2.6. p24 immunoblot analysis of virus and HIV-1 infected cells

After sampling the media for use in p24 determination, the cells were pelleted and the supernatant was harvested. The cells were washed twice with PBS and then lysed with 100 µl lysis buffer per million cells (lysis buffer: 0.75% triton X-100, 300 mM NaCl, 50 mM Tris-HCl, pH 7.4, 0.4% DMSO and 0.5× of Halt protease inhibitor cocktail from Pierce (Rockford, IL)). Immunoblot analysis of the cells was carried out on 2 µg of total protein. Following removal of the cells by centrifugation the virus was pelleted from the supernatant by ultracentrifugation at 45,000 rpm and washed once with cold PBS containing 10 µM of a potent HIV-1 protease inhibitor, ritonavir (to prevent any additional polyprotein processing taking place during the washing steps). The viral pellets were lysed and resuspended in 25 µl SDS sample buffer. Viral samples of equal volume (4 µl) were then run on SDS gels and transferred to nitrocellulose. Blots were then analyzed for the presence of Gag and processed forms of Gag, including p24, with a monoclonal p24 antibody (Advanced Bioscience Laboratories, Kensington, MD) as described previously (Davis et al., 1999).

3. Results

3.1. HIV-1 protease interface peptides with a cell permeable domain (CPD) from HIV-1 tat inhibit the HIV-1 protease

In order to evaluate HIV-1 protease dimerization inhibitors as potential inhibitors of HIV-1 replication, we designed various peptides containing sequences previously reported to inhibit protease dimerization (Babé et al., 1992; Ishima et al., 2003; Shultz and Chmielewski, 1999; Ulysse and Chmielewski, 1998) with a 13 amino acid cell permeable peptide (CPP), (RKKRRQRRRPQV) containing the CPD from HIV-1 Tat (RKKRRQRRR) (Brooks et al., 2005; Fawell et al., 1994; Vives et al., 1997).




Fig. 1. Amino acid sequence and distinct domains for peptide 27 (P27) and 27A (P27A) (A) and the Zhang–Poorman plot for the inhibition of HIV-1 protease by P27A (PQITLRKKRRQRRRPPQVSNFNC/ATLNF) or acetyl pepstatin (B). E represents the active enzyme concentration determined by active site titration and K_{exp} represents the rate of the reaction $K_{exp} = v/[S]$. (●), No inhibitor; (■), P27A 20 µM; (▲), acetyl pepstatin 20 nM.

These peptides were then screened for inhibition of protease activity at 50 µM using a commercially available fluorimetric HIV-1 protease assay. Peptide 27 (P27) (PQITLRKKRRQRRRPPQVSNFNC/ATLNF) designed as shown in Fig. 1A was the most effective inhibitor in this assay and when tested in a peptide based RP-HPLC protease assay carried out as described previously (Davis et al., 1997). At 50 µM, P27 inhibited the protease by more than 90%. With the use of various truncations of P27 it was found that the cell permeable peptide (CPP) (RKKRRQRRRPPQV) alone was inactive while removal of the SFNFCTLNF sequence (containing the C terminal four amino acids of p6 and the C-terminal five amino acids of protease) resulted in a substantial loss in activity (data not shown). Replacement of the cysteine in P27 with alanine to create P27A had little effect on its inhibitory activity and therefore P27A was used in kinetic studies to avoid any potential problems that could arise from cysteine oxidation. To verify that this peptide functioned as a dimerization inhibitor of the protease we carried out the Zhang and Poorman kinetic analysis used for studying dissociative inhibitors of dimeric enzymes (Zhang et al., 1991). If a compound acts as a dimerization inhibitor of the HIV-1 protease, the resulting Zhang–Poorman plot gives a line with a slope similar to that obtained for the untreated control but with a different intercept. A non-dissociative inhibitor, such as an active-site inhibitor, yields a line with a different slope from the untreated control. As shown in Fig. 1B, inhibition of HIV-1 protease by P27A resulted in a line with a similar slope to the untreated buffer control (P27A slope

3.5 ± 0.41 (average \pm standard deviation), versus the control slope 4.1 ± 0.42) but with a significantly different Y -intercept (P27A y -intercept 1.2 ± 0.05 , control y -intercept 0.54 ± 0.05). The results are consistent with P27A acting as a dimerization inhibitor. By contrast, use of the active-site inhibitor, acetyl pepstatin, resulted in a line with a significantly different slope (slope 10.9 ± 3.1) as compared to the untreated enzyme, which is indicative of a non-dissociative inhibitor (Fig. 1B). As determined from the y -intercepts, the K_i for P27A was calculated to be $17 \pm 3 \mu\text{M}$. We also found that unlike that seen with an active site inhibitor, inhibition of HIV-1 protease activity by P27 and P27A was dependent on the time of pre-incubation with the enzyme and inversely dependent on enzyme concentration (data not shown), both of which are characteristic of dimerization inhibitors (Zhang et al., 1991) (data not shown).

3.2. P27 and P27A inhibit PI resistant HIV-1 protease

We also assessed the ability of P27 and P27A to inhibit a PI resistant form of the HIV-1 protease. The resistant protease, designated R1, carries eight PI-resistant mutations (L10I, I15V, I54V, L63P, A71V, V82T, L90M, and I93L) (Muzammil et al., 2003; Ridky and Leis, 1995) and shows high-level resistance to a number of different active site PIs in in vitro resistance assays (Yoshimura et al., 1999). R1 also has a C95F mutation at the dimer interface, therefore a PI-resistant protease without the mutation at position 95 (R1_{F95C}) was also created to determine if the mutation near the dimer interface affected the activity of P27 and P27A. The IC_{50} 's for P27 and P27A were determined for the WT, R1, and R1_{F95C} protease using the fluorescence-based HIV-1 protease assay and the values are reported in Table 1. P27 and P27A were both effective inhibitors of WT and drug-resistant proteases with IC_{50} 's ranging from 0.23 to 0.58 μM . Overall, P27 was about two-fold more active than P27A although there was little difference in the potency of the two peptides between WT and resistant proteases (Table 1). Interestingly, P27 and P27A had similar activity toward the PI-resistant protease with or without the C95F mutation (Table 1).

3.3. Fluorescein-labeled P27A enters living MT-2 cells

To verify that P27 could be taken up by living cells, we treated MT-2 cells with N-terminal fluorescein-labeled P27A. As a positive control, a fluorescein labeled version of CPP (F-CPP) was also tested. When MT-2 cells were treated with F-CPP for 1 h in media containing 10% serum and imaged under fluorescence

microscopy, more than half the cells showed accumulation of the peptide (Fig. 2). Only living cells were fluorescent while none of the dead cells, stained with trypan blue, accumulated the F-CPP peptide. In addition, not all living cells took up the peptide providing evidence that the fluorescence was not a result of non-specific binding to the cells. Similarly, treatment of cells with fluorescein labeled P27A (F-P27A) led to the accumulation of the peptide in the cells (Fig. 2). Again, only living cells accumulated the peptide while dead cells did not. The extent of peptide accumulation appeared to be lower for F-P27A than F-CPP, perhaps due to a tendency of F-P27A to aggregate. Aggregates of F-P27A can be seen in the phase contrast image but they do not fluoresce presumably due to self-quenching of the fluorescein (Fig. 2). Nevertheless, these studies indicated that the peptide accumulated in MT-2 cells and therefore could be potentially useful as an inhibitor of HIV-1 replication.

3.4. P27 protects MT-2 cells from HIV-1 induced cytotoxicity and inhibits p24 accumulation in the supernatant of chronically infected H9 and U937 cells

The ability of P27 and control peptides to block acute HIV-1 infection was assessed in MT-2 cells. MT-2 cells were infected for 2 h with HIV-1_{LAI} and then added to media containing the test peptides. The ability of the peptides to block HIV-1-induced cytotoxicity was determined by measuring the viability of the cells 7 days later using the MTT assay. Two control peptides, CPP (RKKRRRQRRRPPQV) and CPP-SFNF (RKKRRRQRRRPPQVSFNF), that were inactive against the protease were also tested in the assay and compared to P27. CPP and CPP-SFNF were inactive in the acute infection assay when tested up to 50 μM (Fig. 3A and B). However, P27 (PQITLRKKRRRQRRRPPQVSFNFCTLN) protected cells from HIV-1 induced cytotoxicity in a dose-dependent manner with an IC_{50} of 5.1 μM (Fig. 3C). The positive control lopinavir had an IC_{50} of 2 nM (Fig. 3D). The inhibition of virus-induced toxicity by a number of different peptides evaluated in this assay correlated directly with their ability to inhibit protease activity. Although P27A also had some activity at low concentrations of the peptide, it was toxic to uninfected MT-2 cells at concentrations (>5 μM) similar to those required by P27 to provide greater than 50% protection (data not shown).

The effect of P27 on HIV-1 replication was also investigated in H9 cells chronically infected with a WT or a PI-resistant HIV-1 clone. Chronically infected cells that continually produce HIV-1 were washed and then treated with 5 μM of each

Table 1
 IC_{50} values for P27 and P27A using the HIV-1 protease fluorimetric assay

| Peptide | Sequence | IC_{50} (μM) | | |
|---------|-----------------------------|------------------------------------|-----------------|---------------------------------|
| | | WT ^a | R1 ^b | R1 _{F95C} ^c |
| P27 | PQITLRKKRRRQRRRPPQVSFNFCTLN | 0.37 | 0.23 | 0.28 |
| P27A | PQITLRKKRRRQRRRPPQVSFNFATLN | 0.58 | 0.51 | 0.53 |

^a WT: Wild type HIV-1 protease.

^b R1: Drug resistant HIV-1 protease containing F95.

^c R1_{F95C}: Drug resistant HIV-1 protease containing C95.




Fig. 2. Cellular accumulation of fluorescein-labeled peptides containing the cell permeable domain of HIV-1 Tat. MT-2 cells were treated with 30 μM F-CPP (F-RKKRRQRRRPPQV), or 30 μM F-P27A and then incubated for 1 h. The cells were stained with trypan blue to assess viability and then visualized under phase contrast (PC) and fluorescent (F_{520}) microscopy. Shown is a single image for each treatment as seen under PC or F_{520} . Arrows indicate living cells showing accumulation of fluorescent peptides. Note that none of the dead cells (stained with trypan blue in phase contrast image) showed accumulation of the peptides.




Fig. 3. Inhibition of the cytopathic effect of HIV-1 by the P27 protease dimerization inhibitor and control peptides. MT-2 cells were exposed to 100TCID₅₀ of HIV-1_{LAI} for 2 h (●) and then incubated in the presence of 0.21, 0.62, 1.85, 5.56, 16.7 or 50 μM of (A) CPP (RKKRRQRRRPPQV), (B) CPP-SFNF (RKKRRQRRRPPQVSFNF), (C) P27 (PQITLRKKRRQRRRPPQVSFNFCTLNF) or (D) in the presence of the active site protease inhibitor lopinavir at 0.0005, 0.005, 0.05, 0.5, 5 or 50 μM . Viability was assessed using the MTT assay 7 days after infection. Cellular toxicity of the compounds was also assessed in MT-2 cells not exposed to HIV-1 (■). The calculated 50% inhibitory concentrations (IC_{50}) and the 50% cell cytotoxic concentrations (CC_{50}) are indicated within each figure. The values plotted are the average of samples run in triplicate and the error bars show the positive standard deviation.

peptide and the level of mature capsid protein (p24) in the supernatant was determined 4 days later. P27 (5 μ M) inhibited p24 production by approximately 50% in cells infected with wild type HIV-1 while having little effect on cell viability. The CPP and CPP-SFNF peptides, however, had little or no effect on p24 accumulation (Fig. 4A). At 5 μ M, P27 inhibited p24 production in cells infected with PI-resistant virus by 60%, while 5 μ M ritonavir was only weakly active (Fig. 4B). The inhibition of p24 by the different peptides paralleled their ability to inhibit protease activity (Fig. 4C) suggesting that P27 likely affects some aspect of viral maturation involving protease. In addition, dose-dependent inhibition of p24 production was observed when chronically infected U937 cells were treated with P27A (Fig. 5). At 5 μ M, P27A inhibited p24 production by more than 85%, while having little effect on cell viability (Fig. 5).

3.5. Western blot of virus and infected cells treated with P27

To further characterize the antiviral effect of P27, immunoblot analysis was carried out on viral supernatant from chronically infected H9 cells treated with the peptides. As expected, ritonavir treatment, used as a positive protease inhibitor control, resulted in a decrease in p24 and an increase in p55 Gag and p165 Gag-Pol in the virus released from infected cells (Fig. 6A). Treatment of cells with P27 also led to a dose-dependent decrease in p24 (Fig. 6A) comparable to that from the p24 ELISA. However, it did not result in a corresponding increase in p55 Gag. At the same time, treatment with P27 did lead to the accumulation of unidentified high molecular weight proteins detected with the p24 antibody, suggesting a partial inhibition of Gag-Pol processing (Fig. 6A). These results suggested that P27 might inhibit p24 accumulation in the media by blocking virus release, perhaps as a result of disordered Gag-Pol processing. To investigate this possibility, we analyzed the presence of viral proteins in the infected cells treated with P27 by p24 immunoblot. As expected, treatment with ritonavir inhibited polyprotein processing within cells as indicated by the complete absence of a p24 band and the presence of unprocessed forms of p55 Gag (Fig. 6B). By contrast, treatment of cells with P27 resulted in increased levels of p24 within the cells (Fig. 6B). Very similar results were obtained from the supernatant and cell lysates of cells infected with PI-resistant virus (data not shown).

3.6. P27 enhances the effect of potent active-site inhibitors used at suboptimal concentrations

We next analyzed the effect of a combination of suboptimal concentrations of P27 and potent active-site inhibitors on HIV-1 replication in cells infected with wild type HIV-1. As shown in Fig. 7, treatment of cells with 1 μ M ritonavir, saquinavir or KNI-272 resulted in the partial inhibition of p55 Gag processing. The addition of 1 μ M P27 with 1 μ M of each of these active-site inhibitors resulted in a further inhibition of p24 production as evidenced by a decrease in p41 Gag and an increase in p55 Gag and with ritonavir and saquinavir p165 Gag-Pol precursors (Fig. 7). The enhanced block of polyprotein processing was observed with all three of the active-site inhibitors tested, and indicated that suppression of protease activity can be observed with P27 at least when administered with a partially suppressive concentration of an active site inhibitor.




Fig. 4. P27 inhibits p24 production by chronically infected cells and inhibits HIV-1 protease activity. H9 cells chronically infected with WT (rHIV-1_{A01}) (A) or PI-resistant (rHIV-1_{A2F95C}) virus (B) were treated with 5 μ M CPP (RKRRQRPPQV), 5 μ M CPP-SFNF (RKRRQRPPQVSFNF), 5 μ M P27 or the active site protease inhibitor ritonavir (5 μ M) as a positive control and incubated for 3 days in triplicate wells. The supernatants were analyzed for p24 antigen (ng ml⁻¹) (—) and the cells were assessed for viability (Y2-axis) (●), as described in Section 2. The results represent the average \pm the standard deviation for samples run in triplicate. In (C) protease was treated with 1 μ M of each peptide and incubated for 30 min. Enzyme activity was measured as described in Section 2. The results represent the average \pm the standard deviation for samples run in triplicate.

sors (Fig. 7). The enhanced block of polyprotein processing was observed with all three of the active-site inhibitors tested, and indicated that suppression of protease activity can be observed with P27 at least when administered with a partially suppressive concentration of an active site inhibitor.




Fig. 5. Dose-dependent inhibition of p24 production by P27A in chronically infected cells. U937 cells chronically infected with wild type HIV-1 were treated in triplicate with P27A (0, 1, 2.5, 5, and 10 µM) and incubated for 4 days. The supernatants from cells were analyzed for p24 antigen (—) and the cells were assessed for viability (---). The values represent the average ± the standard deviation.

4. Discussion

One of the major driving forces behind the development of dimerization inhibitors is the emergence of viral resistance in patients taking currently available active site HIV-1 protease inhibitors. Mutations rarely occur at the dimer interface of the protease (Kuiken et al., 2004; Svicher et al., 2005), suggesting that dimerization inhibitors could be effective against drug resistant mutants acquired during long-term use of active-site inhibitors. Furthermore, a potential advantage of the dimer interface as a target for inhibitor development is that the interface sequences are part of substrate cleavage sites within Gag-Pol and are also involved in direct protein–protein interactions to form the dimer interface (Todd et al., 1998). These two features put constraints on the development of protease interface mutations that could yield resistance. In some cases, however, resistant HIV-1 has been reported to have a C95F mutation at the dimer interface (Ceccherini-Silberstein et al., 2004; Svicher




Fig. 7. Enhanced inhibition of viral polyprotein processing by active site inhibitors when used in combination with P27. H9 cells chronically infected with WT HIV-1 (rHIV-1_{A01}) were treated without (–) or with (+) P27 at 1 µM, in the presence of no treatment (none), 1 µM ritonavir (Rit), 1 µM saquinavir (Saq) or 1 µM kymostatin 272 (KNI-272). Three days after treatment, the supernatant was harvested and pelleted virus was analyzed by Western blot with a monoclonal antibody to p24.

et al., 2005; Yoshimura et al., 1999). P27 and P27A were active against WT HIV-1 protease and PI-resistant HIV-1 protease both with and without the C95F mutation. Interestingly, P27 was more effective against the drug-resistant proteases than WT protease. It has previously been reported that resistance mutations that occur away from the interface in the protease (V82F, V82F/I84V, V82T/I84V, and L90M) can decrease dimer stability making the protease more susceptible to dimerization inhibitors (Xie et al., 1999). The PI-resistant proteases utilized in these experiments contained the V82T and L90M mutations that have been reported to decrease dimer stability (Xie et al., 1999), and this may make these proteases more susceptible to certain dimerization inhibitors as compared to the WT proteases.

P27 inhibited HIV-1-induced cytotoxicity of MT-2 cells and was minimally toxic to uninfected MT-2 cells at the protective concentrations. However, peptides that lacked the N and C terminal interface sequences of the HIV-1 protease did not protect against HIV-1-induced cytotoxicity in the MT-2 assay.




Fig. 6. Effect of P27 on viral polyprotein processing in HIV-1 infected cells. H9 cells chronically infected with WT HIV-1 (rHIV-1_{A01}) were treated with P27 at 0, 5, 10 or 20 µM, or ritonavir (10 µM) for 3 days and then supernatants (A) and cells (B) were analyzed by Western blot using a monoclonal p24 antibody. The band detected just above p55 in the immunoblot of the cell lysates is a cross-reactive protein from the cell lysates and is not found in released virus. The locations of the Gag-Pol-related and p55 Gag related proteins (p55, p47 and p24) are indicated.

The requirement for the interface sequences suggests that the effect is related to a specific effect on some aspect of viral protease activity. P27 was also effective in blocking p24 production from WT and PI-resistant HIV-1 infected cells at concentrations near the K_i determined for protease inhibition. Interestingly, P27 was more effective in blocking p24 production from PI-resistant HIV-1 infected cells than from WT-infected cells, and this parallels the effect of P27 on WT and PI-resistant proteases. Surprisingly, the decrease in p24 could not be clearly attributed to a block in p55 Gag processing. Instead, the data is more consistent with P27 inhibiting the release of virus from the infected cells. Others have reported that HIV-1 assembly and release is highly dependent on the proper timing and activity of HIV-1 protease, and that partial inhibition of protease activity can lead to major defects in the assembly and production of HIV-1 particles (Hill et al., 2005; Kaplan et al., 1993, 1994; Karacostas et al., 1993; Krausslich, 1991). Thus, P27 may be partially affecting protease activity in infected cells, in turn resulting in an inhibition of viral release. Although Western blots of the virus released from P27 treated cells did not show significant increases in p55 Gag, the virus did contain proteins larger than p55 Gag that were detectable with the p24 antibody and that appear to be related to Gag-Pol. These protein bands were not detected in control virus or virus treated with peptides that were inactive on the protease. The nature of these proteins is currently under investigation.

P27 was designed to block protease dimerization, and the activity of this and related peptides in infected cells paralleled the activity against HIV protease (this article and Davis et al., unpublished observations). HIV-1 protease functions at a number of steps during HIV-1 particle maturation. During the initial stages of Gag-Pol processing, Gag-Pol polyproteins dimerize and the precursor-embedded protease then accomplishes the initial cleavages of Gag-Pol as intramolecular events (Pettit et al., 2004). It is only when the protease dimer is cleaved out that it can manifest trans cleavages of Gag and Gag-Pol. Active-site inhibitors are quite potent against the mature, free protease dimer, but are as much as 10,000 times less active toward the embedded, immature protease (Pettit et al., 2004). We hypothesize that a dimer inhibitor like P27 may be equally or even more effective against the immature protease embedded in Gag-Pol than against the mature, free protease dimer, and that the activity of P27 in HIV-infected cells results primarily from partial inhibition or dysregulation of initial Gag-Pol processing. This would be consistent with the results obtained from experiments using P27 in combination with active site inhibitors, where an increase in the inhibition of Gag and Gag-Pol processing was observed. Additional studies are underway to test this hypothesis.

Combination therapy for HIV-1 infection has proven quite successful for the treatment of AIDS and newly developed protease inhibitors would likely be used in combination with other approved drugs. These data suggest that understanding the precise mechanism by which P27 affects polyprotein processing and prevents viral release may lead to the development of more active dimerization inhibitors and new strategies for HIV-1 antiviral therapy.

Acknowledgements

We would like to thank Dr. Petr Kuzmic for use of his data fitting software BatchKi (BioKin, Ltd. Pullman, WA) and helpful discussions throughout this work. We also thank Dr. Shintaro Matsumi for help with generating the PI-resistant molecular clone and Dr. Zhi-Ming Zheng, Dr. Paula Valasco and Irene Reynolds for critical review of the manuscript. This work was supported by the Intramural Research Program of the National Cancer Institute, NIH, and by a grant from the NIH Intramural AIDS Targeted Antiviral Program.

References

- Babé, L.M., Rose, J., Craik, C.S., 1992. Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. *Protein Sci.* 1, 1244–1253.
- Babé, L.M., Rose, J., Craik, C.S., 1995. Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. *Proc. Natl. Acad. Sci. U.S.A.* 92, 10069–10073.
- Bonny, C., Oberson, A., Negri, S., Sausser, C., Schorderet, D.F., 2001. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. *Diabetes* 50, 77–82.
- Brooks, H., Lebleu, B., Vives, E., 2005. Tat peptide-mediated cellular delivery: back to basics. *Adv. Drug Deliv. Rev.* 57, 559–577.
- Cabana, M., Clotet, B., Martinez, M.A., 1999. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. *J. Med. Virol.* 59, 480–490.
- Ceccherini-Silberstein, F., Erba, F., Gago, F., Bertoli, A., Forbici, F., Bellocchi, M.C., Gori, C., D'Arrigo, R., Marcon, L., Balotta, C., Antinori, A., Monforte, A.D., Perno, C.F., 2004. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. *AIDS* 18, F11–F19.
- Chen, L., Wright, L.R., Chen, C.H., Oliver, S.F., Wender, P.A., Mochly-Rosen, D., 2001. Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). *Chem. Biol.* 8, 1123–1129.
- Condra, J.H., Schleif, W.A., Blahy, O.M., Gabryelski, L.J., Graham, D.J., Quintero, J.C., Rhodes, A., Robbins, H.L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teplert, H., Squires, K.E., Deutsch, P.J., Emini, E.A., 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. *Nature* 374, 569–571.
- Datta, K., Sundberg, C., Karumanchi, S.A., Mukhopadhyay, D., 2001. The 104–123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. *Cancer Res.* 61, 1768–1775.
- Davis, D.A., Dorsey, K., Wingfield, P.T., Stahl, S.J., Kaufman, J., Fales, H.M., Levine, R.L., 1996. Regulation of HIV-1 protease activity through cysteine modification. *Biochemistry* 35, 2482–2488.
- Davis, D.A., Newcomb, F.M., Starke, D.W., Ott, D.E., Mieyal, J.M., Yarchoan, R., 1997. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. *J. Biol. Chem.* 272, 25935–25940.
- Davis, D.A., Yusa, K., Gillim, L.A., Newcomb, F.M., Mitsuya, H., Yarchoan, R., 1999. Conserved cysteines of the human immunodeficiency type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. *J. Virol.* 13, 1156–1164.
- Davis, D.A., Newcomb, F.M., Moskovitz, J., Wingfield, P.T., Stahl, S.J., Kaufman, J., Fales, H.M., Levine, R.L., Yarchoan, R., 2000. HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase. *Biochem. J.* 346, 305–311.
- Davis, D.A., Brown, C.A., Newcomb, F.M., Boja, E.S., Fales, H.M., Kaufman, J., Stahl, S.J., Wingfield, P., Yarchoan, R., 2003. Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation. *J. Virol.* 77, 3319–3325.

- Deeks, S.G., Volberding, P.A., 1997. HIV-1 protease inhibitors. *AIDS Clin. Rev.*, 145–185.
- Dumond, J., Boggetto, N., Schramm, H.J., Schramm, W., Takahashi, M., Reboud-Ravaux, M., 2003. Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease. *Biochem. Pharmacol.* 65, 1097–1102.
- Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L.L., Pepinsky, B., Barsoum, J., 1994. Tat-mediated delivery of heterologous proteins into cells. *Proc. Natl. Acad. Sci. U.S.A.* 91, 664–668.
- Flexner, C., 1998. HIV-protease inhibitors. *N. Engl. J. Med.* 338, 1281–1292.
- Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., Sugiura, Y., 2001. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. *J. Biol. Chem.* 276, 5836–5840.
- Futaki, S., Goto, S., Suzuki, T., Nakase, I., Sugiura, Y., 2003. Structural variety of membrane permeable peptides. *Curr. Protein Pept. Sci.* 4, 87–96.
- Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M.F., Nagashima, K., Gorelick, R.J., Mardy, S., Tang, C., Summers, M.F., Mitsuya, H., 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. *J. Biol. Chem.* 277, 5952–5961.
- Hill, M., Tachedjian, G., Mak, J., 2005. The packaging and maturation of the HIV-1 Pol proteins. *Curr. HIV Res.* 3, 73–85.
- Ishima, R., Torchia, D.A., Lynch, S.M., Gronenborn, A.M., Louis, J.M., 2003. Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. *J. Biol. Chem.* 278, 43311–43319.
- Jin, L.H., Bahn, J.H., Eum, W.S., Kwon, H.Y., Jang, S.H., Han, K.H., Kang, T.C., Won, M.H., Kang, J.H., Cho, S.W., Park, J., Choi, S.Y., 2001. Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. *Free Radic. Biol. Med.* 31, 1509–1519.
- Kaplan, A.H., Zack, J.A., Knigge, M., Paul, D.A., Kempf, D.J., Norbeck, D.W., Swanstrom, R., 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of non-infectious particles. *J. Virol.* 67, 4050–4055.
- Kaplan, A.H., Manchester, M., Swanstrom, R., 1994. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. *J. Virol.* 68, 6782–6786.
- Karacostas, V., Wolffe, E.J., Nagashima, K., Gonda, M.A., Moss, B., 1993. Over-expression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. *Virology* 193, 661–671.
- Krausslich, H.-G., 1991. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. *Proc. Natl. Acad. Sci. U.S.A.* 88, 3213–3217.
- Kuiken, C.L., Foley, B., Hahn, B., Korber, B., McCutchan, F., Marx, P.A., Mellors, J.W.I.M.J., Sodroski, J., Wolinsky, S. (Eds.), 2004. HIV Sequence Compendium 2004. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
- Kuzmic, P., Ng, K.Y., Heath, T.D., 1992. Mixtures of tight-binding enzyme inhibitors. Kinetic analysis by a recursive rate equation. *Anal. Biochem.* 200, 68–73.
- Lundberg, M., Wikstrom, S., Johansson, M., 2003. Cell surface adherence and endocytosis of protein transduction domains. *Mol. Ther.* 8, 143–150.
- Misson, J., Clark, W., Kendall, M.J., 1997. Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection. *J. Clin. Pharm. Ther.* 22, 109–117.
- Muzammil, S., Ross, P., Freire, E., 2003. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. *Biochemistry* 42, 631–638.
- Oxford, J.S., Coates, A.R.M., Sia, D.Y., Brown, K., Asad, S., 1989. Potential target sites for antiviral inhibitors of human immunodeficiency virus (HIV). *J. Antimicrob. Chemother.* 23 (Suppl. A), 9–27.
- Park, J., Ryu, J., Jin, L.H., Bahn, J.H., Kim, J.A., Yoon, C.S., Kim, D.W., Han, K.H., Eum, W.S., Kwon, H.Y., Kang, T.C., Won, M.H., Kang, J.H., Cho, S.W., Choi, S.Y., 2002. 9-Polylysine protein transduction domain: enhanced penetration efficiency of superoxide dismutase into mammalian cells and skin. *Mol. Cells* 13, 202–208.
- Pettit, S.C., Everitt, L.E., Choudhury, S., Dunn, B.M., Kaplan, A.H., 2004. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. *J. Virol.* 78, 8477–8485.
- Richard, J.P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M.J., Chernomordik, L.V., Lebleu, B., 2003. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. *J. Biol. Chem.* 278, 585–590.
- Ridky, T., Leis, J., 1995. Development of drug resistance to HIV-1 protease inhibitors. *J. Biol. Chem.* 270, 29621–29623.
- Romano, L., Venturi, G., Giomi, S., Pippi, L., Valensin, P.E., Zazzi, M., 2002. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. *J. Med. Virol.* 66, 143–150.
- Schmit, J.C., Ruiz, L., Clotet, B., Raventos, A., Tor, J., Leonard, J., Desmyter, J., De Clercq, E., Vandamme, A.M., 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). *AIDS* 10, 995–999.
- Schramm, H.J., de Rosny, E., Reboud-Ravaux, M., Buttner, J., Dick, A., Schramm, W., 1999. Lipopeptides as dimerization inhibitors of HIV-1 protease. *Biol. Chem.* 380, 593–596.
- Schwarze, S.R., Ho, A., Vocero-Akbani, A., Dowdy, S.F., 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science* 285, 1569–1572.
- Shafer, R.W., Jung, D.R., Betts, B.J., Xi, Y., Gonzales, M.J., 2000. Human immunodeficiency virus reverse transcriptase and protease sequence database. *Nucleic Acids Res.* 28, 346–348.
- Shafer, R.W., Winters, M.A., Palmer, S., Merigan, T.C., 1998. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. *Ann. Intern. Med.* 128, 906–911.
- Shultz, M.D., Chmielewski, J., 1999. Probing the role of interfacial residues in a dimerization inhibitor of HIV-1 protease. *Bioorg. Med. Chem. Lett.* 9, 2431–2436.
- Svicher, V., Ceccherini-Silberstein, F., Erba, F., Santoro, M., Gori, C., Bellocchi, M.C., Giannella, S., Trotta, M.P., Monforte, A., Antinori, A., Perno, C.F., 2005. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. *Antimicrob. Agents Chemother.* 49, 2015–2025.
- Takenobu, T., Tomizawa, K., Matsushita, M., Li, S.T., Moriwaki, A., Lu, Y.F., Matsui, H., 2002. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. *Mol. Cancer Ther.* 1, 1043–1049.
- Todd, M.J., Semo, N., Freire, E., 1998. The structural stability of the HIV-1 protease. *J. Mol. Biol.* 283, 475–488.
- Tomasselli, A.G., Olsen, M.K., Hui, J.O., Staples, D.J., Sawyer, T.K., Henrikson, R.L., Tomich, C.S., 1990. Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. *Biochemistry* 29, 264–269.
- Ulysse, L.G., Chmielewski, J., 1998. Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease. *Bioorg. Med. Chem. Lett.* 8, 3281–3286.
- Vives, E., Brodin, P., Lebleu, B., 1997. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J. Biol. Chem.* 272, 16010–16017.
- Weber, I.T., 1990. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. *J. Biol. Chem.* 265, 10492–10496.
- Wheeler, D.S., Dunsmore, K.E., Wong, H.R., 2003. Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain. *Biochem. Biophys. Res. Commun.* 301, 54–59.
- Xie, D., Gulnik, S., Gustchina, E., Yu, B., Shao, W., Qoronfleh, W., Nathan, A., Erickson, J.W., 1999. Drug resistance mutations can effect

- dimer stability of HIV-1 protease at neutral pH. *Protein Sci.* 8, 1702–1707.
- Yoshimura, K., Kato, R., Yusa, K., Kavlick, M.F., Maroun, V., Nguyen, A., Mimoto, T., Ueno, T., Shintani, M., Falloon, J., Masur, H., Hayashi, H., Erickson, J., Mitsuya, H., 1999. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. *Proc. Natl. Acad. Sci. U.S.A.* 96, 8675–8680.
- Zhang, Z.Y., Poorman, R.A., Maggiora, L.L., Heinrikson, R.L., Kezdy, F.J., 1991. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. *J. Biol. Chem.* 266, 15591–15594.
- Zutshi, R., Chmielewski, J., 2000. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. *Bioorg. Med. Chem. Lett.* 10, 1901–1903.